MRI demonstrated a lack of recurrent tumor up to 1 year following surgery (Fig. 1A). Neurological side effects of this therapy were moderate and resolved within 3 months. The treated dog experienced transient focal neurologic signs that became more severe with each subsequent vaccine. Specifically, focal seizures, left hemiparesis, and acute blindness as assessed by lack of menace

response in the left eye were documented after the fourth and fifth vaccinations. Left hemiparesis and left-sided blindness became apparent 3 days after the forth and fifth vaccination, and resolved within a week in each instance. In addition, during therapy, the dog exhibited circulating lymphopenia, peripheral lymphadenopathy around the vaccination site, and elevation of gamma glutamyltransferase

(GGT) and alanine aminotransferase (ALT) that were not Selleckchem 3 MA present prior to treatment (Table 1). Although Transmembrane Transporters modulator the elevation of such liver enzymes may have been induced by anti-seizure medication (see Section 4), the timing of the other neurological symptoms 3 days after the fourth and fifth vaccination indicate a possible relationship with the vaccines. In order to detect IgG responses specific to the dog’s own tumor, tumor cell lysates from the autologous cells grown in culture were subjected to SDS-PAGE. Autologous serum harvested before or after vaccinations was used as a primary antibody and specific IgG was detected using anti-canine IgG antibody. Western blot analysis revealed that this dog did not have an appreciable pre-existing tumor-reactive IgG response, and there was no signal from normal canine serum used as a control. By 2 weeks after the first vaccination, IgG reactive to two proteins approximately 50–65 kDa in weight was detected (Fig. 2A). This response remained unchanged 2 weeks later at day 65, but increased in breadth of antigens recognized as subsequent vaccinations were administered. A memory IgG response was induced to three separate tumor antigens,

as revealed by three bands on Western Blot using serum harvested over 100 days following the last vaccination Cediranib (AZD2171) (Fig. 2A). Upon recognition of their cognate antigen, CTLs elaborate IFNγ and release cytotoxic granules; the proteins CD107a, CD107b, and CD63 within the granule mobilize to the cell surface during degranulation (reviewed in [26]). Accordingly, CD107 cell surface mobilization measured by flow cytometry demonstrates a linear correlation with tumor cell lysis [27], and CD107 has been used to monitor CTL responses in melanoma patients treated by vaccination [28]. Because the number of peripheral blood mononuclear cells (PBMCs) obtained from this dog was limited, we elected to employ this flow cytometry-based assay to detect CTL degranulation and IFNγ production. PBMCs frozen at various time points before and after surgery were thawed and analyzed identically and simultaneously to eliminate interexperiment variability.